178 related articles for article (PubMed ID: 37331781)
1. Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.
Earland N; Chen K; Semenkovich NP; Chauhan PS; Zevallos JP; Chaudhuri AA
Semin Radiat Oncol; 2023 Jul; 33(3):262-278. PubMed ID: 37331781
[TBL] [Abstract][Full Text] [Related]
2. Utilizing circulating tumour DNA in radiation oncology.
Rostami A; Bratman SV
Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
4. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA: current challenges for clinical utility.
Dang DK; Park BH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
[TBL] [Abstract][Full Text] [Related]
7. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
8. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
9. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
Moding EJ; Nabet BY; Alizadeh AA; Diehn M
Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
[TBL] [Abstract][Full Text] [Related]
12. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
[TBL] [Abstract][Full Text] [Related]
13. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
Chae YK; Oh MS
J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
15. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
16. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
[TBL] [Abstract][Full Text] [Related]
17. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.
Cifuentes GA; Santiago A; Méndez Blanco L; Fueyo M; López Martínez E; Soria R; Martín López I; Cucarella Beltrán P; Pardo-Coto P; Rodriguez-Rubi D; Urquilla K; Durán NS; Álvarez R; Lago CG; Otero A; Diñeiro M; Capín R; Cadiñanos J; Cabanillas R
Br J Cancer; 2023 Mar; 128(5):857-876. PubMed ID: 36550207
[TBL] [Abstract][Full Text] [Related]
20. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA.
He K; Zhang S; Shao LL; Yin JC; Wu X; Shao YW; Yuan S; Yu J
Cancer Lett; 2020 Mar; 472():108-118. PubMed ID: 31837443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
